Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial

Hyun Cheol Chung, Hendrik-Tobias Arkenau, Jeeyun Lee, Sun Young Rha, Do-Youn Oh, Lucjan Wyrwicz, Yoon-Koo Kang, Keun-Wook Lee, Jeffrey R. Infante, Sung Sook Lee, Margaret Kemeny, Ulrich Keilholz, Bohuslav Melichar, Alain Mita, Ruth Plummer, Denis Smith, Arnold B. Gelb, Huiling Xiong, Janet Hong, Vikram Chand, Howard Safran

Open source

DOI: 10.1186/s40425-019-0508-1
Published: 2019-02-04
Container: Journal for ImmunoTherapy of Cancer
Publisher: BMJ
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s40425-019-0508-1,
  title = {Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial},
  author = {Hyun Cheol Chung and Hendrik-Tobias Arkenau and Jeeyun Lee and Sun Young Rha and Do-Youn Oh and Lucjan Wyrwicz and Yoon-Koo Kang and Keun-Wook Lee and Jeffrey R. Infante and Sung Sook Lee and Margaret Kemeny and Ulrich Keilholz and Bohuslav Melichar and Alain Mita and Ruth Plummer and Denis Smith and Arnold B. Gelb and Huiling Xiong and Janet Hong and Vikram Chand and Howard Safran},
  year = {2019},
  journal = {Journal for ImmunoTherapy of Cancer},
  doi = {10.1186/s40425-019-0508-1},
  url = {https://doi.org/10.1186/s40425-019-0508-1}
}

RIS

TY  - JOUR
TI  - Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial
AU  - Hyun Cheol Chung
AU  - Hendrik-Tobias Arkenau
AU  - Jeeyun Lee
AU  - Sun Young Rha
AU  - Do-Youn Oh
AU  - Lucjan Wyrwicz
AU  - Yoon-Koo Kang
AU  - Keun-Wook Lee
AU  - Jeffrey R. Infante
AU  - Sung Sook Lee
AU  - Margaret Kemeny
AU  - Ulrich Keilholz
AU  - Bohuslav Melichar
AU  - Alain Mita
AU  - Ruth Plummer
AU  - Denis Smith
AU  - Arnold B. Gelb
AU  - Huiling Xiong
AU  - Janet Hong
AU  - Vikram Chand
AU  - Howard Safran
PY  - 2019
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1186/s40425-019-0508-1
UR  - https://doi.org/10.1186/s40425-019-0508-1
ER  -

APA

Chung, H. C., Arkenau, H., Lee, J., Rha, S. Y., Oh, D., Wyrwicz, L., Kang, Y., Lee, K., Infante, J. R., Lee, S. S., Kemeny, M., Keilholz, U., Melichar, B., Mita, A., Plummer, R., Smith, D., Gelb, A. B., Xiong, H., Hong, J., Chand, V., & Safran, H. (2019). Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1186/s40425-019-0508-1

Source records

crossref · retrieved 2026-09-26T01:22:39.948Z